|
|
|
|
 |
|
 About Genexol > Overview > Action mechanism |
|
|
|
 |
|
|
|
|
Paclitaxel shows relatively low toxicity and high anticancer activity by stabilizing microtubules during cell mitosis.
This unique action mechanism has enabled it to become one of the most widely used anticancer substances in the 1990s.
The FDA (United States) approved Paclitaxel for ovarian cancer in 1992, breast cancer in 1994, and Kaposi's sarcoma in 1997.
The need for paclitaxel is expected to grow 30% annually, and will further increase after completion of the on-going process
of over 180 clinical trials for combination therapies, and for the new application against non-small cell lung cancer, rheumatoid
arthritis.
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
